Filter Publications
Product
Year
October 2025
Initial Clinical Experience With the Oral Cholate ChallengeTest: Results From the 2023–2024 Early Access Program
| Liver International Communications | October 2025
The oral cholate challenge test of liver health, intended for use in compensated advanced chronic liver disease, was launched through an Early Access Program (EAP) in 2023–2024. Tests were provided to 16 clinicians at five liver centres across the US. The tested patients (n = 129) represented a range of etiologies and stages of disease. Top clinical uses were: (1) informing the decision for endoscopy to test for varices (n = 56, 43%), (2) defining risk for large oesophageal varices (LEV) (n = 92, 71%), and (3)baseline for monitoring disease progression or treatment effects (n = 33, 26%). The test's disease severity index (DSI) stratified patients according to risk for portal hypertension and LEV: 49 (38%) low risk, 31 (24%) moderate risk and 49 (38%) high risk. The potential impact of DSI ≤ 18.3 on EGD avoidance (38%) in clinical practice replicated that which was observed in prior validation studies (41%). read more →
HepQuant DuO
September 2025
Cholate clearance: improving the assessment of liver health compared to current liver tests (LFTs)
| Gastro Hep Advances | September 2025
Current liver function tests (LFTs) either indicate late-stage disease or hepatobiliary injury but do not accurately measure liver function. True quantitative liver function tests, analogous to creatinine clearance for the kidneys, are needed for assessing liver health. read more →
HepQuant DuO
August 2025
The Cholate Challenge Test Quantified Baseline Functional Heterogeneity and Improvement in Response to Resmetirom in MASH-related Child Pugh A Cirrhosis
| Gastro Hep Advances | August 2025
In this study of MASH-related Child-Pugh A cirrhosis (MASH cirrhosis), we used the cholate challenge test to quantify baseline disease severity and the subsequent impact of resmetirom treatment. read more →
HepQuant DuO
April 2025
Assessment of the performance of a dual-sample oral cholate challenge test: The HepQuant DuO test
| Clinica Chimica Acta | April 2025
Liver health is currently evaluated using nonspecific blood tests, fibrosis surrogates, and invasive procedures, none of which directly measure liver function and physiology. The validated HepQuant SHUNT test quantifies liver function and physiology and is linked to clinical outcomes. Herein we present the reliability of a simplified version, the dual-sample oral cholate challenge (HepQuant DuO) test. read more →
HepQuant DuO
March 2025
Letter to the Editor: Enhancing the Diagnostic Performance of the Oral Cholate Challenge Test: Implications for Avoidance of Potentially Unnecessary Endoscopy
| Alimentary Pharmacology & Therapeutics| March 2025
HepQuant DuO, HepQuant SHUNT